Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Postictal Hyperactive Delirium in ECT: Management with Midazolam.

Edward H. Liston1, David E. Sones

  • 1Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine and the UCLA Neuropsychiatric Institute and Hospital, Los Angeles, California, USA.

Convulsive Therapy
|January 1, 1990
PubMed
Summary

Midazolam (MDZ), a new benzodiazepine, effectively treated or prevented postictal hyperactive delirium (PHD) in electroconvulsive therapy patients. This study found MDZ to be safe and well-tolerated, offering a promising option for managing PHD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychiatry Resident and Medical Student Perspectives on ECT: Influence of Exposure and Education.

Convulsive therapy·1992
Same author

Electroconvulsive Therapy and Brain Glucose Metabolism.

Convulsive therapy·1991
Same author

Patient and Family Perspectives of Electroconvulsive Therapy: Correlation with Outcome.

Convulsive therapy·1991
Same author

Hemodynamic Responses to ECT After Bilateral Adrenalectomy.

Convulsive therapy·1990
Same author

Monitoring Electroconvulsive Therapy by Galvanic Skin Response.

Convulsive therapy·1988
Same author

Informing Patients About Electroconvulsive Therapy: Effects of a Videotape Presentation.

Convulsive therapy·1986

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Postictal hyperactive delirium (PHD) is a potential complication during electroconvulsive therapy (ECT).
  • Effective management strategies for PHD are crucial for patient safety and treatment continuity.

Purpose of the Study:

  • To evaluate the safety and efficacy of midazolam (MDZ) as a treatment or prophylactic agent for PHD in patients undergoing ECT.
  • To review the clinical pharmacology of MDZ in the context of PHD management.

Main Methods:

  • An open, uncontrolled clinical trial involving 21 patients who experienced episodes of PHD during ECT.
  • Administration of midazolam (MDZ) for sedation and management of PHD.

Main Results:

Related Experiment Videos

  • Midazolam (MDZ) was found to be safe in all 21 patients.
  • MDZ demonstrated efficacy in treating or preventing PHD in at least 20 patients.
  • Key pharmacological properties include rapid onset, brief duration, fast metabolism, and versatile administration routes.

    • Conclusions:

    • Midazolam (MDZ) is a safe and effective agent for the management of postictal hyperactive delirium (PHD) in ECT patients.
    • Its favorable pharmacokinetic and safety profile makes it an attractive option for PHD treatment and prophylaxis.